Tirzepatide: what it is and what the research actually shows

In “Doctor Explains Retatrutide: The Most Powerful GLP-1 Weight Loss Drug Yet”, Dr. Alex Tatem discusses Tirzepatide. What he says, in short:

• He explains tirzepatide added GIP receptor activity on top of GLP-1, which stimulates more insulin release and uniquely drives fat burning via adipose tissue blood flow, unlike semaglutide which only hits the GLP-1 receptor.
• From the SURMOUNT-1 trial at 72 weeks he reports the 5 mg dose averaged 15% weight loss, the 10 mg dose 19.5%, and the 15 mg dose 20.9%, with about 50 to 57% of patients on the top doses losing over 20% of body weight.
• He says its GI related side effects were similar to the other GLP-1 drugs, with discontinuations only in the single digits.
• He says retatrutide's 24 to 48 week results look steeper than or on par with tirzepatide's 72 week results, but notes there is no approved head to head trial yet, only one currently ongoing.
• He frames semaglutide and tirzepatide as the legitimate options currently available while retatrutide finishes trials.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

In “Retatrutide Dosing Explained (Doctor Breaks Down the Data)”, Dr. Alex Tatem discusses Tirzepatide. What he says, in short:

• He describes tirzepatide (Mounjaro) as a dual agonist acting on the GLP-1 and GIP receptors, making it more powerful than semaglutide alone.
• He compares tirzepatide's 72 week trial to retatrutide's 80 week Triumph 1 data, noting the differing trial lengths mean the gap isn't a clean apples to apples comparison.
• He predicts that once retatrutide reaches market it will behave like tirzepatide does now, with most people titrating to an effective, tolerated dose rather than pushing straight to the ceiling dose.
• He ranks the GLP-1 drugs in a hierarchy where retatrutide beats tirzepatide, and tirzepatide beats semaglutide.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

In “The GLP-1 Revolution: Weight Loss Drugs That ACTUALLY Work”, Dr. Ashley Froese discusses Tirzepatide. What she says, in short:

• She says she has treated hundreds of patients with semaglutide and tirzepatide, and gives the example of a patient named Maria who lost 80 pounds on tirzepatide and says she no longer constantly obsesses about food.
• She frames GLP-1 medications like tirzepatide as working by reversing insulin resistance, which she says she's come to see as the root of almost every major health problem.
• She says tirzepatide and semaglutide make sense for people with meaningful weight to lose, or with pre-diabetes, diabetes, fatty liver, high blood pressure, sleep apnea, strong food noise, or binge eating that hasn't responded to diet and therapy.
• She lists reasons to skip or delay it: personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, pregnancy, trying to conceive soon, breastfeeding, a past pancreatitis, gastroparesis, or gallstone or kidney issues to discuss with a doctor first.
• She warns women on tirzepatide who use birth control pills to use a backup contraception method for one week after starting or after any dose increase, because tirzepatide slows the gut enough to lower how much of the pill gets absorbed.
• She advises starting at a low dose and titrating up slowly, treating the first 4 to 8 weeks as a settling-in phase rather than peak weight loss, and says roughly 80% of the patients she puts on these medications see a lot of success while 10 to 20% don't respond or find the side effects too much.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Dr. Explains Why Retatrutide is KING of Fat Loss Peptides”, Dr. Ashley Froese discusses Tirzepatide. What she says, in short:

• She explains tirzepatide adds GIP agonism to GLP-1, saying this gives fewer side effects and more weight loss than semaglutide, which is pure GLP-1, alone.
• She says GIP receptors in the brain dampen the nausea signal from GLP-1 agonism, so tirzepatide can suppress appetite while easing nausea.
• She describes GIP as triggering a "futile calcium cycle" that raises energy expenditure and oxygen use in brown fat, temporarily boosting metabolism.
• She cites study figures of roughly 15% average weight loss with GLP-1 alone versus 20 to 25% with tirzepatide's combined GLP-1 and GIP action.
• She mentions friends' reports of chronic diarrhea resolving on tirzepatide, which she says fits with GLP-1 drugs' effect on gut motility.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver” on Andrew Huberman, Dr. Craig Koniver discusses Tirzepatide. What he says, in short:

• He says his clinic has used tirzepatide primarily for about the past two years and calls it something like semaglutide version 2.0.
• He says his own opinion changed from working with people, having started out cautious about dependency and about patients losing too much weight.
• He says conventional dosing makes people lose weight too fast, so his clinic has it compounded in order to use micro dosages and start very low.
• He says that as long as people lose two pounds or less a week they are not losing muscle mass, and that his clinic also encourages adequate protein and resistance training.
• He calls the microdosing approach a game changer, contrasting it with earlier patients who lost about 15 pounds in three weeks and then either regained it or lost facial fat in the way he describes as looking skeletal.
• He says that beyond weight loss he is now seeing cognitive benefits and lower inflammatory markers, including in autoimmune patients, and says he cannot tell whether that is a direct immune effect, an indirect result of losing fat tissue, or the positive mindset that follows.
• He says his philosophy is to help people win the race first so they get motivated to train for the next one, rather than requiring the lifestyle work up front.
• He says he does not claim it has to be taken for life, but that when something works and as far as he can tell is very safe, he likes people having the option.

we get uh both semaglutide mostly tepati compounded and that allows us to use basically micro dosages and start very low in terms of dosage and go slowly with people

and now beyond the weight loss you know we're seeing cognitive benefits we're seeing you know inflammation benefits

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Dr. Craig Koniver | Peptides, Ozempic, Stem Cells, NAD, Mindset | Ep. 219” on Danica Patrick, Dr. Craig Koniver discusses Tirzepatide. What he says, in short:

• He names tirzepatide together with semaglutide as his first answer when asked what he would give someone for weight loss, saying they work so well.
• He says his own approach is to use it only for a short period, which for most people he puts at two or three months.
• He says he does not buy into the messaging that a person has to be on it for the rest of their life.
• He describes checking in with patients every few weeks to confirm they are still losing weight and feeling good, and pulling back if they are not.
• He says compounding kept the cost down, and that once these become pharmaceuticals cost goes up and access goes down, citing roughly $1,500 a month or more for people whose insurance does not cover it.
• He says the brand name patent is in the injector pen rather than the molecule, and that the material works just as well without the pen and is a lot cheaper.

for people the tepati and semaglutide works so well my thing is we just want to use it for a short period of time

I just don't buy into the fear that is being messaged that oh you have to be on the rest of your life that is not true

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Use This Peptide Stack To Get Toned & Lose Weight FAST Before Summer (Doctor Explains)”, Dr. Jones, DC discusses Tirzepatide. What he says, in short:

• He calls tirzepatide the tried and true option, describes it as a dual agonist at the GLP-1 and GIP receptors, and says its appetite suppression is excellent and very predictable.
• He says if food chatter is the main battle, tirzepatide is the move, and that this is the deciding factor rather than which molecule is newest.
• He says people who are not on a GLP-1 should start at the lowest effective dose, arguing even a low dose can quiet food noise enough for everything else in the stack to work.
• He places tirzepatide as appetite control only, the first of three systems, and insists that without something handling appetite the rest of the stack falls apart.
• He cites studies on GLP-1 medications showing somewhere between 25 and 40 percent of the weight lost is lean muscle tissue, which he uses to argue for a muscle preservation layer alongside it.
• He says some of his patients run both tirzepatide and retatrutide at the lowest effective dose rather than choosing one.

Tirzepatide is what I call the tried and true option. It's a dual agonist, a GLP-1 and a GIP receptor. Excellent appetite suppression, very predictable.

Studies on GLP-1 meds show that somewhere between 25% to 40% of the weight people lose is lean muscle tissue.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “The ULTIMATE Peptide Stack For Fat Loss & Metabolic Flexibility! | Dr. Jones DC”, Dr. Jones, DC discusses Tirzepatide. What he says, in short:

• He defines a microdose as his own opinion, naming 2.5 for tirzepatide and 0.25 for semaglutide or anything lower.
• He says the collaboration between him and his providers is to get patients to the lowest dose possible, which he says requires being aggressive with lifestyle interventions.
• He reports as clinic experience that patients stay at 2.5 on tirzepatide and never have to increase, and that anything above 5 is really high for them and rare.
• He criticizes what he calls the cookie-cutter template most practitioners follow, which he characterizes as doubling the dose every four weeks with little variation.
• He pushes back on the claim that GLP-1s cause muscle loss on their own, arguing the driver is massive appetite suppression plus uncoached nutrition, while conceding faster weight loss likely increases the rate of muscle loss.
• He names his three levers for protecting muscle during weight loss as hypertrophy-style weight training, adequate protein, and optimized testosterone.
• He voices a caution about the modification that stretched natural GLP-1 half-life from minutes to a week, saying the chronic stimulation concerns him and that long-term studies on the earlier shorter-acting agents are not the same thing.
• He says he thinks GLP-1s should be used toward medication independence rather than indefinitely, while adding that if he were forced onto one medication for life this would be it.

Microdosing means anything lower than, you know, I consider in my opinion a microdose 2.5 for tirzepatide, 0.25 for semaglutide, or anything lower than that.

GLP-1s don't cause muscle mass loss on their own.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.